DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Australia
  • /
  • Healthcare
Author Program NEWCreate Narrative
NAN logo

Nanosonics Limited Stock Price

ASX:NAN Community·AU$825.0m Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 53 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NAN Share Price Performance

AU$2.76
-1.29 (-31.85%)
​
AU$3.85
Fair Value
AU$2.76
-1.29 (-31.85%)
28.4% undervalued intrinsic discount
AU$3.85
Fair Value
Price AU$2.76
AnalystConsensusTarget AU$3.85
AnalystLowTarget AU$3.00
AnalystHighTarget AU$5.43
Wed, 9 Sep 26
Fair ValueAU$3.85
Share Pricen/a

NAN Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value AU$3.85 28.4% undervalued intrinsic discount

Automated Disinfection Solutions Will Transform Hospital Safety Worldwide

1users have liked this narrative
1users have commented on this narrative
28users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value AU$3 8.0% undervalued intrinsic discount

Rising Hospital Cost Containment And Tech Obsolescence Will Erode Profitability

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value AU$5.43 49.2% undervalued intrinsic discount

Rising Global Aging And Regulatory Demands Will Accelerate Automated Disinfection

1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
NAN logo
Nanosonics
28.4% undervalued intrinsic discount
Updated

Automated Disinfection Solutions Will Transform Hospital Safety Worldwide

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 9 Sep
Read Narrative
NAN logo
Nanosonics
8.0% undervalued intrinsic discount

Rising Hospital Cost Containment And Tech Obsolescence Will Erode Profitability

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 26 Aug
Read Narrative
NAN logo
Nanosonics
49.2% undervalued intrinsic discount

Rising Global Aging And Regulatory Demands Will Accelerate Automated Disinfection

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 18 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
NAN logo

NAN: Share Buyback And 2027 Guidance Will Support Future Upside Potential

Fair Value: AU$3.85 28.4% undervalued intrinsic discount
28 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
NAN logo

NAN: Share Buybacks And Lower Profitability Assumptions Will Shape Future Performance

Fair Value: AU$3 8.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
NAN logo

NAN: Lower Discount Rate And Margins Assumed To Support Future Upside

Fair Value: AU$5.43 49.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
1 Reward
View Full Analysis

Nanosonics Limited Key Details

AU$203.9m

Revenue

AU$47.1m

Cost of Revenue

AU$156.8m

Gross Profit

AU$139.0m

Other Expenses

AU$17.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.06
76.91%
8.75%
0%
View Full Analysis

About NAN

Founded
2000
Employees
508
CEO
Michael Kavanagh
WebsiteView website
www.nanosonics.com.au

Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In addition, it is involved in the research, development, and commercialization of the CORIS system, an automated technology designed to transform flexible endoscope reprocessing. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Recent NAN News & Updates

User avatar
Narrative Update • Sep 09

NAN: Share Buyback And 2027 Guidance Will Support Future Upside Potential

Analysts have revised their price target on Nanosonics to A$3.85 from A$4.30, citing updated views on revenue growth, profit margins, and future P/E assumptions as key drivers of the change. What’s in the News for Nanosonics Nanosonics has announced a share repurchase program that allows the company to buy back up to $40 million of its shares, with purchased shares to be cancelled as part of its capital management approach.
User avatar
Narrative Update • Aug 26

NAN: Share Buybacks And Lower Profitability Assumptions Will Shape Future Performance

Analysts have trimmed their 12 month price target for Nanosonics from A$3.60 to A$3.00, citing updated assumptions for lower revenue growth, reduced profit margins and a higher expected P/E multiple, which together point to a more conservative fair value profile. What’s in the News for Nanosonics Nanosonics has announced a share repurchase program, with plans to buy back up to A$40 million of its shares as part of its capital management approach.

Recent updates

No updates

Nanosonics Limited Competitors

4DX logo

4DMedical

Symbol: ASX:4DX
Market cap: AU$2.0b
REG logo

Regis Healthcare

Symbol: ASX:REG
Market cap: AU$1.4b
IDX logo

Integral Diagnostics

Symbol: ASX:IDX
Market cap: AU$849.3m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide